Gastroesophageal Adenocarcinoma Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Gastroesophageal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast-2034" Report delivers an in-depth understanding of the Gastroesophageal Adenocarcinoma, historical and forecasted epidemiology as well as the Gastroesophageal Adenocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Gastroesophageal Adenocarcinoma Market Share @ Gastroesophageal Adenocarcinoma Market Outlook- https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Gastroesophageal Adenocarcinoma Market Report
• In May 2025, Merck Sharp & Dohme LLC announced a study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
• In 2023, the total Incident Cases of Gastroesophageal adenocarcinoma was above 220,000 in the 7MM.
• Among the 7MM, Japan accounted for the highest number of incident cases of gastroesophageal adenocarcinoma in 2023.
• Among EU4 and the UK, Germany accounts for the highest and Spain for the lowest number of Incident Cases of Gastroesophageal adenocarcinoma.
• Gastroesophageal adenocarcinoma was observed to more common in males than females
• In the US, Stage IV accounted for the highest number of incident cases of Gastroesophageal adenocarcinoma, while in Japan, highest cases were observed in Stage I.
• The increase in Gastroesophageal Adenocarcinoma Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Gastroesophageal Adenocarcinoma Market is anticipated to witness growth at a considerable CAGR.
• The leading Gastroesophageal Adenocarcinoma Companies such as Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others.
• Promising Gastroesophageal Adenocarcinoma Therapies such as KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others

Stay ahead in the Gastroesophageal Adenocarcinoma Therapeutics Market with DelveInsight's Strategic Report @ Gastroesophageal Adenocarcinoma Market Outlook- https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroesophageal Adenocarcinoma Epidemiology Segmentation in the 7MM
• Total Gastroesophageal Adenocarcinoma Prevalence Cases
• Prevalent Cases of Gastroesophageal Adenocarcinoma by severity
• Gastroesophageal Adenocarcinoma Gender-specific Prevalence Cases
• Gastroesophageal Adenocarcinoma Diagnosed Cases of Episodic and Chronic Cases

Download the report to understand which factors are driving Gastroesophageal Adenocarcinoma Epidemiology trends @ Gastroesophageal Adenocarcinoma Prevalence- https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroesophageal Adenocarcinoma Marketed Drugs
• KEYTRUDA (pembrolizumab): Merck
On May 5, 2021, the FDA granted accelerated approval to pembrolizumab (brand name KEYTRUDA) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastroesophageal adenocarcinoma. Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin (pruritus), diarrhea, nausea, rash, fever (pyrexia), cough, difficulty breathing (dyspnea), constipation, pain, and abdominal pain. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, allowing the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.

• LONSURF (trifluridine/ tipiracil): Taiho Pharmaceuticals
In February 2019, FDA approved trifluridine/ tipiracil tablets, a fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, for adult patients with metastatic gastroesophageal adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, platinum, either a taxane or irinotecan and if appropriate, HER2/neu-targeted therapy. The most common side effects of LONSURF when used include low blood counts, tiredness and weakness, nausea, decreased appetite, diarrhea, vomiting, stomach-area (abdominal) pain, and fever.

Gastroesophageal Adenocarcinoma Emerging Drugs
• Sacituzumab Tirumotecan (MK-2870): Merck/Sichuan Kelun-Biotech
Sacituzumab tirumotecan is an investigational antibody-drug conjugate that consists of an antibody-targeting trophoblast cell-surface antigen 2 (TROP2) linked to a belotecan-derived payload. Sacituzumab tirumotecan is being developed as monotherapy and/or in combination with KEYTRUDA. It is being developed in collaboration with Sichuan Kelun-Biotech. Currently, it is in Phase III for treatment in 3L+ Advanced/Metastatic Gastroesophageal adenocarcinoma.

• Evorpacept (ALX148): ALX Oncology
In advanced HER2-positive gastric and gastroesophageal junction cancer patients, ALX148, a CD47 blocker developed by ALX Oncology, showed enhanced treatment response when used as a second- or third-line therapy alongside trastuzumab, ramucirumab, and paclitaxel. This improvement was observed compared to treatment with trastuzumab, ramucirumab, and paclitaxel alone. These findings were consistent even among patients previously treated with fam-trastuzumab deruxtecan-nxki (ENHERTU) and checkpoint inhibitor therapy. Currently, ALX148 is in Phase II of its development process.

Gastroesophageal Adenocarcinoma Treatment Market Landscape
The Gastroesophageal Adenocarcinoma treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Gastroesophageal Adenocarcinoma has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Gastroesophageal Adenocarcinoma treatment guidelines, visit @ Gastroesophageal Adenocarcinoma Treatment Market Landscape- https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroesophageal Adenocarcinoma Market Outlook
The report's outlook on the Gastroesophageal Adenocarcinoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Gastroesophageal Adenocarcinoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Gastroesophageal Adenocarcinoma drug and late-stage pipeline therapy.

Gastroesophageal Adenocarcinoma Drugs Uptake
The drug chapter of the Gastroesophageal Adenocarcinoma report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Gastroesophageal Adenocarcinoma.

Gastroesophageal Adenocarcinoma Therapies and Key Companies
• KEYTRUDA (pembrolizumab): Merck
• LONSURF (trifluridine/ tipiracil): Taiho Pharmaceuticals
• Sacituzumab Tirumotecan (MK-2870): Merck/Sichuan Kelun-Biotech
• Evorpacept (ALX148): ALX Oncology
• Paclitaxel: Canadian Cancer Trials Group
• Trifluridine-Tipiracil: Merck Sharp & Dohme LLC
• ASKB589: AskGene Pharma, Inc.
• AK104: Akeso
• OBP-301: Weill Medical College
• tucatinib: Seagen Inc.
• Docetaxel for injection (Albumin-bound): CSPC ZhongQi Pharmaceutical
• Zanidatamab: Jazz Pharmaceuticals
• Trastuzumab deruxtecan: Daiichi Sankyo
• Capecitabine: RemeGen Co., Ltd.
• Infigratinib: LianBio LLC
• Atezolizumab: Hoffmann-La Roche
• Bemarituzumab: Amgen
• PT886: Phanes Therapeutics

Learn more about the FDA-approved drugs for Gastroesophageal Adenocarcinoma @ Drugs for Gastroesophageal Adenocarcinoma Treatment- https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Gastroesophageal Adenocarcinoma Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Gastroesophageal Adenocarcinoma Companies- Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others.
Gastroesophageal Adenocarcinoma Therapies- KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others• Gastroesophageal Adenocarcinoma Market Dynamics: Gastroesophageal Adenocarcinoma Market Drivers and Barriers
• Gastroesophageal Adenocarcinoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Gastroesophageal Adenocarcinoma Drugs in development @ Gastroesophageal Adenocarcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/gastroesophageal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Gastroesophageal Adenocarcinoma Executive Summary
3. Gastroesophageal Adenocarcinoma Competitive Intelligence Analysis
4. Gastroesophageal Adenocarcinoma: Market Overview at a Glance
5. Gastroesophageal Adenocarcinoma: Disease Background and Overview
6. Patient Journey
7. Gastroesophageal Adenocarcinoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Gastroesophageal Adenocarcinoma Unmet Needs
10. Key Endpoints of Gastroesophageal Adenocarcinoma Treatment
11. Gastroesophageal Adenocarcinoma Marketed Products
12. Gastroesophageal Adenocarcinoma Emerging Therapies
13. Gastroesophageal Adenocarcinoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Gastroesophageal Adenocarcinoma Market Outlook
16. Access and Reimbursement Overview of Gastroesophageal Adenocarcinoma
17. KOL Views
18. Gastroesophageal Adenocarcinoma Market Drivers
19. Gastroesophageal Adenocarcinoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

Radiation retinopathy market- https://www.delveinsight.com/sample-request/radiation-retinopathy-market
Immune checkpoints activators market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Cystic fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Palmoplantar pustulosis market- https://www.delveinsight.com/report-store/palmoplantar-pustulosis-market
Smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Tay-Sachs market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Open angle glaucoma market- https://www.delveinsight.com/report-store/glaucoma-market
Acute myeloid leukemia market- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market
Asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiogenic shock market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
Pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
Pelizaeus-merzbacher disease market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
Peritoneal carcinomatosis market- https://www.delveinsight.com/report-store/peritoneal-carcinomatosis-pc-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.